News List

Thursday July 31, 2008 Confirmation of the Strong Growth over the First Half of 2008

Luminy, 31 July 2008 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and commercialization of molecular diagnostic tests for cancer, today announces its revenue for its first half to 30...

Category: Investors

Sunday June 29, 2008 Ipsogen accelerates its development in Europe with the CE marking of its JAK2 diagnostic kits

Ipsogen’s JAK2 V617F diagnostic kits are now available to all European diagnostic laboratories

Category: Leukemia, Investors

Tuesday June 10, 2008 Ipsogen announces the success of the offer that ended on 9 June 2008 and its listing on Alternext

Luminy, 10 June, 2008 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and marketing of molecular diagnostic tests for cancer, announces the success of the offer that ended on 9 June...

Category: Investors

Monday June 02, 2008 Ipsogen's Initial Public Offering on Alternext

Luminy, June 2, 2008 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player  in the development and marketing of molecular diagnostic tests for cancer, announces that the Autorité de marchés financiers (AMF)...

Category: Investors

Friday May 30, 2008 Ipsogen launches MapQuant Dx™ Genomic Grade test to identify breast cancer patients who benefit from chemotherapy

IPSOGEN SA (Marseilles, France and New Haven, CT, USA), a cancer profiler that markets molecular diagnostic assays for leukaemia announced today that it is entering the breast cancer diagnostic market with the European launch of...

Category: Breast Cancer

Friday May 23, 2008 Ipsogen announces the official AMF registration of its “Document de base” under the n° I.08-058 on May 22, 2008

 Ipsogen announces the official AMF registration of its “Document de base” under the n° I.08-058 on May 22, 2008.

More

Category: Investors

Monday May 19, 2008 Ipsogen announces three studies at the American Society of Clinical Oncology (ASCO) meeting extending the utility of the Genomic Grade index for predicting response to chemotherapy in breast cancer

IPSOGEN SA (Marseille and New Haven), a cancer profiler that develops and markets molecular diagnostic assays for blood & breast cancers, announced today that researchers from the University of Texas MD Anderson Cancer Center...

Category: Breast Cancer

Monday January 21, 2008 Ipsogen reports recommendation of JAK2V617F mutation screening in World Health Organization 2008 criteria and point-of-care diagnostic algorithms

Ipsogen SAS today reported that the 2008 revision of the WHO document on the classification of chronic myeloproliferative diseases (CMPDs) hasincorporated new information on the molecular pathogenesis of BCR–ABL negative...

Category: Leukemia

Tuesday January 08, 2008 Ipsogen licenses the Genomic Grade™ to improve Breast Cancer diagnosis & treatment decision

IPSOGEN SAS, a leading molecular diagnostic company based in France and Connecticut, USA announced today the signature of a license agreement with Université Libre de Bruxelles (ULB), Belgium for the worldwide and exclusive...

Category: Breast Cancer

Monday December 03, 2007 Ipsogen to undertake pilot study on JAK2 cancer biomarker with AstraZeneca

IPSOGEN, a leading molecular diagnostic company based in France andConnecticut, USA today announced that it has entered into a pilot agreement with AstraZeneca to evaluate molecular services and products in cancer research.Under...

Category: Leukemia